Tugyna-500 coated tablets 500 mg. №10


Bleeding or risk of bleeding with increased fibrinolysis as generalized (bleeding during prostate and postoperative surgery, hemorrhagic complications of fibrinolytic therapy), and local (uterine, nasal bleeding, posttraumatic hepatitis, bleeding, bleeding, bleeding cervix, extraction of a tooth in patients with hemophilia). Hereditary angioneurotic edema.



Composition and form of release
The drug Tugin-500 is produced in the form of white or almost white biconvex film-coated tablets. The tablets have a capsule-like shape and a fracture line on one side, and on the other hand engraving “500”. The main element of the preparation in the composition is designated tranexamic acid 500 mg, as additional components are provided: corn starch, microcrystalline cellulose, croscarmellose sodium, colloidal silicon dioxide, stearic acid, magnesium stearate, isopropyl alcohol, titanium dioxide, dichloromethane. In a cardboard box, 1 blister with 10 tablets is packed.
Pharmacological properties
Tugina-500 is an antifibrinolytic drug, which is used if they need to stop the blood during surgical interventions, after injuries, in case of bleeding disorders and bleeding of internal organs, as well as in many other areas of treatment. The drug has anti-inflammatory and anti-allergic effects.
The drug Tugin-500 is used for bleeding or if there is a risk of bleeding during exacerbation of fibrinolysis as generalized (bleeding during surgery on the prostate gland and during the period after surgery, hemorrhagic complications during fibrinolytic treatment). This drug is also prescribed for local bleeding (epistaxis, uterine, post-traumatic hephema, cervical conization, bleeding after prostatectomy, interventions on the bladder, tooth extraction in patients with hemophilia). The indication for the use of tablets is also hereditary angioedema.
The drug Tugin-500 has a number of contraindications for use: the patient has intolerance to the components that make up the drug, macroscopic hematuria, renal failure, increased risk of thrombus formation, myocardial infarction, thrombophlebitis, a history of convulsions, subarachnoid hemorrhage, acute arterial or venous … Also, Tugin-500 tablets cannot be taken in fibrinolytic conditions after coagulopathy due to exhaustion, with the exception of excessive activation of the fibrinolytic system in acute severe bleeding.
Application during pregnancy and lactation
The use of the drug Tugin-500 during pregnancy is possible only if there is a threat to the life of a pregnant woman. During breastfeeding, taking the drug is contraindicated.
Method of administration and dosage
For local fibrinolysis, it is recommended to use Tugin-500 in a dose of 2-3 tablets (15-25 mg / kg body weight) 2-3 times a day.
For post-traumatic hephema, 2-3 tablets of the drug are used every 8 hours. Duration of treatment is 6-7 days.
With menorrhagia, the recommended dose of Tugin-500 is 2 tablets (1 g). The duration of therapy is no more than 4 days. The permissible daily dose should not exceed 8 tablets (4 g). Therapy should be started at the onset of visible bleeding and continued throughout the first 4 days of the menstrual cycle. After three months of treatment, the patient must be examined.
For prostatectomy, 2 tablets (1 g) are used 6 hours before the operation, after the intervention, 2 tablets 3-4 times a day until macroscopic hematuria disappears. The duration of therapy is no more than 2 weeks.
When conization of the cervix, 2-3 tablets of the drug are used every 8-12 hours. Duration of treatment is up to 12 days.
In hemophilia, the recommended dose is 25 mg / kg of the drug with an interval of 8 hours, start therapy 1 day before the operation and 2 days after it.
With hereditary angioedema, 2-3 tablets are used 2-3 times a day. The duration of therapy can be several days or over a long period of time, it depends on the course of the disease.
For patients with impaired renal function, the dose of the drug is adjusted according to the level of creatinine clearance. If the clearance is 120 – 250 μmol / l, the dose is 10 mg / kg of body weight 2 times a day. Clearance 250 – 500 μmol / l dose is 10 mg / kg body weight every day. Clearance of more than 500 μmol / L dose is 5 mg / kg of body weight daily.
In case of an overdose of Tugin-500, the following symptoms may occur: vomiting, orthostatic hypotension, nausea, dizziness, abdominal pain, arterial hypotension, headache, convulsions, or an increase in side effects, including the risk of thrombosis, may occur. In cases of intoxication, induce vomiting, gastric lavage, then take activated charcoal. It is necessary to consume plenty of fluids and apply symptomatic treatment.

Side effects
The use of Tugin-500 can cause side effects, such as: hypersensitivity reactions, nausea, heartburn, vomiting and diarrhea, decreased appetite, abdominal pain, rash, allergic skin reactions and itching, drowsiness, convulsions and dizziness. Also, taking pills can lead to impaired vision and color perception, congestive retinopathy, occlusion of the retinal artery, thromboembolic complications, venous thrombosis of various localization, acute necrosis of the renal cortex, arterial hypotension.
Storage conditions and periods
Storage conditions of the drug Tugina-500: original packaging, inaccessible to children, temperature not higher than + 25 ° C. The shelf life of the drug is 2 years.